Latest & greatest articles for furosemide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on furosemide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on furosemide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for furosemide

1. Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight

Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight 29752171 2018 08 01 1097-6833 199 2018 Aug The Journal of pediatrics J. Pediatr. Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Infants of Very Low Birth Weight. 231-236 S0022-3476(18)30479-7 10.1016/j.jpeds.2018.03.067 To evaluate the association between furosemide exposure and patent ductus arteriosus (PDA) in a large, contemporary cohort (...) regression to evaluate the association between PDA and exposure to furosemide. We included 43 576 infants from 337 neonatal intensive care units, of whom 6675 (15%) underwent PDA treatment. Infants with PDA were more premature and more often exposed to mechanical ventilation and inotropes. Furosemide was prescribed to 4055 (9%) infants. On multivariable regression, exposure to furosemide was associated with decreased odds of PDA treatment (OR 0.72; 95% CI 0.65-0.79). Increasing percentage of days

EvidenceUpdates2018

2. Furosemide

Furosemide Top results for furosemide - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for furosemide The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Temporal bone histopathology of furosemide ototoxicity

Temporal bone histopathology of furosemide ototoxicity 29085910 2018 11 13 2378-8038 2 5 2017 10 Laryngoscope investigative otolaryngology Laryngoscope Investig Otolaryngol Temporal bone histopathology of furosemide ototoxicity. 204-207 10.1002/lio2.108 To describe the human temporal bone pathology in two patients who incurred furosemide induced ototoxicity. 1) A 46-year-old woman in acute liver and renal failure treated with high doses of furosemide for anasarca who developed a rapidly (...) progressive severe-to-profound asymmetric sensorineural hearing loss. 2) A 65-year-old woman with undifferentiated small cell carcinoma of the lung who received intravenous furosemide 1 day prior to death for pulmonary edema. Removal of temporal bones, histologic processing, and light microscopy of temporal bones. Temporal bone histopathology and correlation with clinical and audiometric data. All three temporal bones demonstrated edema and cystic changes in the stria vascularis. In the first case

Laryngoscope investigative otolaryngology2017 Full Text: Link to full Text with Trip Pro

4. Peritoneal Dialysis vs Furosemide for Prevention of Fluid Overload in Infants After Cardiac Surgery: A Randomized Clinical Trial

Peritoneal Dialysis vs Furosemide for Prevention of Fluid Overload in Infants After Cardiac Surgery: A Randomized Clinical Trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2017

5. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.

Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. 27818782 2016 11 07 2017 02 20 2055-5822 3 3 2016 Sep ESC heart failure ESC Heart Fail Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. 177-188 Loop diuretics are first-line medications for congestive heart failure (CHF); however, they are associated with serious adverse effects, including decreased renal (...) function, and sympathetic nervous and renin-angiotensin system activation. We tested whether tolvaptan, a vasopressin V2-receptor antagonist, could reduce unfavourable furosemide-induced effects during CHF treatment. Sixty patients emergently hospitalized owing to CHF-induced dyspnea were randomly assigned to receive either 40 mg intravenous furosemide daily or 7.5 mg oral tolvaptan for 5 days after admission. Both groups also received intravenous carperitide and canrenoate potassium. As results

ESC heart failure2016 Full Text: Link to full Text with Trip Pro

6. Comparison of Intraoperative Aminophylline Versus Furosemide in Treatment of Oliguria During Pediatric Cardiac Surgery

Comparison of Intraoperative Aminophylline Versus Furosemide in Treatment of Oliguria During Pediatric Cardiac Surgery PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2016

7. Furosemide sc2Wear micro-pump patch for oedema in heart failure

Furosemide sc2Wear micro-pump patch for oedema in heart failure Furosemide sc2Wear micro-pump patch for oedema in heart failure Furosemide sc2Wear micro-pump patch for oedema in heart failure NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Furosemide sc2Wear micro-pump patch for oedema in heart failure. Birmingham: NIHR Horizon Scanning (...) and surrounding tissue. Furosemide sc2Wear micro-pump patch is intended to treat patients with heart failure who have increased fluid in their lungs and other tissues. This treatment aims to reduce hospital stay for patients who suffer a worsening of their heart failure. The sc2Wear micro-pump delivers the drug just under the skin by a wearable patch, rather than requiring hospital treatment where drugs are given directly into the blood by a drip. If furosemide sc2Wear micro-pump is licensed for use in the UK

Health Technology Assessment (HTA) Database.2016

8. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial

Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial 19535188 2009 09 28 2009 10 02 2015 11 19 1523-6838 54 4 2009 Oct American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing (...) coronary angiography: a randomized controlled trial. 602-9 10.1053/j.ajkd.2009.03.024 Contrast-induced nephropathy is common in patients with coronary angiography. Mechanistically, forced euvolemic diuresis with mannitol and furosemide ought to prevent contrast-induced nephropathy. Our objectives are to: (1) undertake a randomized trial testing this hypothesis, and (2) conduct a meta-analysis of our findings with 2 earlier studies. (1) Randomized allocation-concealed controlled trial with blinded

EvidenceUpdates2010

9. High dose furosemide plus small volume hypertonic saline solutions (HSS) vs repeated paracentesis as treatment of refractory ascites: a randomized pilot study

High dose furosemide plus small volume hypertonic saline solutions (HSS) vs repeated paracentesis as treatment of refractory ascites: a randomized pilot study 19438847 2009 07 23 2010 02 22 2013 11 21 1365-2036 30 3 2009 Aug Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. 227-35 10.1111/j.1365-2036.2009.04040.x In patients (...) with cirrhosis, ascites is defined as refractory when it cannot be mobilized or recurs early in standard diuretic therapy. To compare the safety and efficacy of intravenous high-dose furosemide + hypertonic saline solutions (HSS) with repeated paracentesis in patients with cirrhosis and refractory ascites. Eighty-four subjects (59/25 M/F) with cirrhosis, mostly of viral aetiology, admitted for refractory ascites, were randomly assigned to receive furosemide (250-1000 mg/bid i.v.) plus HSS (150 mL H(2)O

EvidenceUpdates2009

10. Narrative review: furosemide for hypercalcemia: an unproven yet common practice.

Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Although primary hyperparathyroidism is the most common cause of hypercalcemia, cancer is the most common cause requiring inpatient intervention. An estimated 10% to 20% of all patients with cancer have hypercalcemia at some point in their disease trajectory, particularly in advanced disease. Aggressive saline hydration and varying doses of furosemide continue to be the standard of care for emergency management (...) . However, a review of the evidence for the use of furosemide in the medical management of hypercalcemia yields only case reports published before the introduction of bisphosphonates, in contrast to multiple randomized, controlled trials supporting the use of bisphosphonates. The use of furosemide in the management of hypercalcemia should no longer be recommended.

Annals of Internal Medicine2008

11. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury

A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2008

12. Nebulized furosemide for the management of dyspnea: does the evidence support its use?

Nebulized furosemide for the management of dyspnea: does the evidence support its use? Nebulized furosemide for the management of dyspnea: does the evidence support its use? Nebulized furosemide for the management of dyspnea: does the evidence support its use? Newton P J, Davidson P M, Macdonald P, Ollerton R, Krum H CRD summary The authors concluded that nebulized furosemide appeared to have a positive effect on dyspnoea and physiological measurements, but the conclusions were limited (...) by the small scale or methodological limitations of many included studies. Given the unclear quality of the included studies, the reliability of the authors' conclusions is unclear and their caution is justified. Authors' objectives To evaluate the effectiveness of nebulized furosemide in the management of dyspnoea. Searching MEDLINE, EMBASE, CINAHL and the Internet were search for articles in English between 1988 and 2006. Search terms were reported. Bibliographies of identified articles were searched

DARE.2008

13. Narrative review: furosemide for hypercalcemia. An unproven yet common practice

Narrative review: furosemide for hypercalcemia. An unproven yet common practice Narrative review: furosemide for hypercalcemia. An unproven yet common practice Narrative review: furosemide for hypercalcemia. An unproven yet common practice LeGrand S B, Leskuski D, Zama I CRD summary This review concluded that evidence does not support the use of furosemide in common practice as the primary treatment of hypercalcaemia of any cause. Given several limitations with the included studies and review (...) , including small sample size, indirect treatment comparisons and potential bias, and the paucity of current evidence, the authors' conclusions should be interpreted with extreme caution. Authors' objectives To examine the evidence on the use of furosemide as the primary therapy for hypercalcaemia. Searching MEDLINE (1950 to April 2008), the American College of Physicians Journal Club, the Cochrane Database of Systematic Reviews and DARE were searched for articles in English; articles in French were also

DARE.2008

14. Albumin and furosemide for acute lung injury

Albumin and furosemide for acute lung injury Albumin and furosemide for acute lung injury | Critical Care | Full Text Advertisement Search BioMed Central articles Search Impact Factor 4.950 Main menu Journal club critique Open Access Albumin and furosemide for acute lung injury Asjad Khan , Eric B Milbrandt and Ramesh Venkataraman Critical Care 2007 11 :314 DOI: 10.1186/cc6135 © BioMed Central Ltd 2007 Published: 27 September 2007 Expanded Abstract Citation Martin GS, Moss M, Wheeler AP, Mealer (...) M, Morris JA, Bernard GR: A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med 2005, 33:1681–1687 [ ]. Background Hypoproteinemia is a common condition in critically ill patients, associated with the development of acute lung injury and acute respiratory distress syndrome and subsequent worse clinical outcomes. Albumin with furosemide benefits lung physiology in hypoproteinemic patients with acute lung injury

Critical Care - EBM Journal Club2007 Full Text: Link to full Text with Trip Pro

15. Drugs - Furosemide (Frusemide, Lasix)

Drugs - Furosemide (Frusemide, Lasix) Furosemide (Frusemide, Lasix) FRM Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Ampoules containing furosemide 50 milligrams/5ml. OR Ampoules containing furosemide 40 milligrams/2ml. OR Pre-?lled syringe containing furosemide 80 milligrams. ACTIONS Furosemide is a potent diuretic with a rapid onset (within 30 minutes) and short duration. DOSAGE AND ADMINISTRATION Route: IV ADDITIONAL INFORMATION Nitrates are the first line treatment for acute pulmonary (...) oedema. Use furosemide secondary to nitrates in the treatment of acute pulmonary oedema where transfer times to hospital are prolonged. CAUTIONS Hypokalaemia (low potassium) could induce arrhythmias. Pregnancy. INDICATIONS Pulmonary oedema secondary to Left Ventricular failure (LVF). CONTRA-INDICATIONS Pre-comatose state secondary to liver cirrhosis, severe renal failure with anuria. Children <16 years. SIDE EFFECTS Hypotension. Gastro-intestinal disturbances. Administer SLOWL Y over 2 minutes. AGE

Joint Royal Colleges Ambulance Liaison Committee2007

16. Furosemide (Frusemide, Lasix)

Furosemide (Frusemide, Lasix) Furosemide (Frusemide, Lasix) FRM Drugs October 2006 Page 1 of 1 Drugs PRESENTATION Ampoules containing furosemide 50 milligrams/5ml. OR Ampoules containing furosemide 40 milligrams/2ml. OR Pre-?lled syringe containing furosemide 80 milligrams. ACTIONS Furosemide is a potent diuretic with a rapid onset (within 30 minutes) and short duration. DOSAGE AND ADMINISTRATION Route: IV ADDITIONAL INFORMATION Nitrates are the first line treatment for acute pulmonary oedema (...) . Use furosemide secondary to nitrates in the treatment of acute pulmonary oedema where transfer times to hospital are prolonged. CAUTIONS Hypokalaemia (low potassium) could induce arrhythmias. Pregnancy. INDICATIONS Pulmonary oedema secondary to Left Ventricular failure (LVF). CONTRA-INDICATIONS Pre-comatose state secondary to liver cirrhosis, severe renal failure with anuria. Children <16 years. SIDE EFFECTS Hypotension. Gastro-intestinal disturbances. Administer SLOWL Y over 2 minutes. AGE DOSE

Joint Royal Colleges Ambulance Liaison Committee2006

17. Nebulised Furosemide in Acute Adult Asthma

Nebulised Furosemide in Acute Adult Asthma BestBets: Nebulised Furosemide in Acute Adult Asthma Nebulised Furosemide in Acute Adult Asthma Report By: Zui-Shen Yen, MD, MPH - Emergency Physician Search checked by Shyr-Chyr Chen, MD - Emergency Physician Institution: National Taiwan University Hospital Date Submitted: 23rd June 2005 Date Completed: 26th August 2005 Last Modified: 28th June 2005 Status: Green (complete) Three Part Question In [an adult with asthma] is [nebulised beta agonist (...) with nebulised furosemide better than nebulised beta agonist alone] at [improving airflow and reducing morbidity]? Clinical Scenario A known asthmatic adult patient is brought into the emergency department with signs consistent with acute asthma. Little improvement is noted with nebulised beta agonist therapy. You wonder if adjunctive nebulised furosemide would provide any benefit. Search Strategy Medline 1966-12/04 and Embase: Drugs & Pharmacology 1980-1/03 using the OVID interface, The Cochrane Library

BestBETS2005

18. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury

Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2002

19. Furosemide for transient tachypnea of the newborn.

Furosemide for transient tachypnea of the newborn. BACKGROUND: Transient tachypnea of the newborn results from delayed clearance of lung liquid and is a common cause of admission of full term infants to neonatal intensive care units. The condition is particularly common after elective Caesarean section. Conventional treatment involves appropriate oxygen administration and continuous positive airway pressure in some cases. Most infants receive antibiotic therapy. Hastening the clearance of lung (...) liquid should shorten the duration of the symptoms and reduce complications. OBJECTIVES: To determine whether furosemide reduces the duration of oxygen therapy and respiratory symptoms and shortens hospital stay in term infants with transient tachypnea of the newborn. SEARCH STRATEGY: We searched the Cochrane Controlled Trials Register, PubMed and EMBASE. The primary author and experts in the field were contacted. SELECTION CRITERIA: Randomised or quasi-randomised controlled trials. Infants of less

Cochrane2002

20. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants.

Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. BACKGROUND: Inhibition of prostaglandin synthesis mediates closure of the ductus arteriosus and renal side effects after indomethacin administration. Because furosemide increases prostaglandin production, it could potentially help prevent indomethacin-related toxicity but also decrease ductal response to indomethacin. OBJECTIVES: The primary objectives of this review were to assess (1) whether furosemide (...) affects the incidence of failure of ductal closure after indomethacin and that of indomethacin-related toxicity and (2) the effect of furosemide on mid-term and long-term outcome. The secondary objective was to determine whether the effect of furosemide on renal function and water balance depends on prior extracellular volume (assessed by blood urea nitrogen [BUN]/creatinine ratio). SEARCH STRATEGY: We searched electronic databases (Medline, Embase and Cochrane) and selected abstract books, without

Cochrane2001